Skip to main content

Press
Job offers
Investors
- Investors
- SHARES
- AGENDA
- CORPORATE GOVERNANCE
- SUSTAINABILITY REPORT
- ETHICS AND ANTI-CORRUPTION
  - 5.1 Charters and codes
- FINANCIAL INFORMATION
- SHAREHOLDER'S MEETING
  - 7.1 General meeting date and venue
  - 7.2 Meeting notice published in the French publication for legal announcements (BALO)
  - 7.3 Board's report on the remuneration policy
  - 7.5 Delegations of authority for capital increases at the end of the reporting period
  - 7.6 Universal Registration Document (URD)
  - 7.7 Statutory auditors'report on regulated agreements
  - 7.8 Board's report on corporate governance
  - 7.9 List of directors and offices
  - 7.10 Description of the share buyback program
  - 7.11 Statutory Auditors'report on the draft resolutions submitted to the meeting
  - 7.12 Document request form
  - 7.13 Form for voting by both mail or proxy
  - 7.14 Total number of voting rights existing and the number of shares comprising the capital on the publication date of the notice mentioned in article 225-73 of the French commercial Code, specifying, as applicable the number of shares and voting rights
  - 7.15 As applicable, the text and presentation of the reasons for the draft resolutions presented by shareholders
  - 7.16 As applicable, the list of items added to the agenda by the shareholders, accompanied by comments of the Board on these items.
  - 7.17 As applicable, the response of the Board to written questions submitted by the shareholders
  - 7.18 Meeting notice published in the BALO at D-15
  - 7.19 Video of the General Meeting
  - 7.20 Results of the votes
  - 7.21 Proceedings of the General Meeting
- PRESS RELEASES
- REGULATED INFORMATION
  - 9.1 Annual report
  - 9.2 Half year report
  - 9.3 Quaterly data
  - 9.4 Monthly Information on the total number of voting rights and the number of shares
  - 9.5 Description of the share buyback programs
  - 9.6 Permanent information
  - 9.10 Information on shareholding threshold
- CONTACTS
  - 10.1 Account Manager intermediary contact
  - 10.2 Press and Communications agency contact
- LEGAL NOTICE
2025 Key figures

€526 million
2,486 people
Essential products: €334m

VETOQUINOL LIVE SHARE PRICE

2025 results: 526 M€

Lastest press releases

05 Feb. 2026

Buyback programs -January 2026

05 Feb. 2026

Monthly information regarding the total number of voting rights – January 2026

29 Jan. 2026

Annual sales 2025: €526 million

en
fr

Fulltext search

Select country

Europe

Austria

Belgium

Czech Republic

France

Germany

Ireland

Italy

Netherlands

Poland

Portugal

Slovakia

Spain

Sweden

Switzerland

United Kingdom

America

Brazil

Canada

Mexico

USA

Asia

China

India

Japan

South Korea

Oceania

Australia

New Zealand

Main navigation

Who are we?
- Vetoquinol’s mission and vision
- Vetoquinol’s key figures
- Achieve More Together with Vetoquinol
- Vetoquinol’s culture and values
- Vetoquinol’s history
- Research & Development (R&D) at Vetoquinol
- International production sites
- Vetoquinol's management & organisation
- Vetoquinol around the world
Products
- By species
- Cat and dog medical products
- Cattle farming medical products
- Pig farming medical products
- By domains
- Mobility, pain & inflammation
- Dermatology, hygiene & care
- Udder health
- Anti-parasite
- Antibiotics
- Reproduction
- Internal medicine
- Cardio-nephrology
- Behaviour management
Careers
- Vetoquinol's company values
- Inclusion & diversity at Vetoquinol
- Work at Vetoquinol
- Job vacancies at Vetoquinol
Responsibility
- Corporate responsibility
- Vetoquinol's commitment to sustainability
- Corporate sponsorships
- Partnerships with Vetoquinol
News

Press
Job offers
Investors
- Investors
- SHARES
- AGENDA
- CORPORATE GOVERNANCE
- SUSTAINABILITY REPORT
- ETHICS AND ANTI-CORRUPTION
  - 5.1 Charters and codes
- FINANCIAL INFORMATION
- SHAREHOLDER'S MEETING
  - 7.1 General meeting date and venue
  - 7.2 Meeting notice published in the French publication for legal announcements (BALO)
  - 7.3 Board's report on the remuneration policy
  - 7.5 Delegations of authority for capital increases at the end of the reporting period
  - 7.6 Universal Registration Document (URD)
  - 7.7 Statutory auditors'report on regulated agreements
  - 7.8 Board's report on corporate governance
  - 7.9 List of directors and offices
  - 7.10 Description of the share buyback program
  - 7.11 Statutory Auditors'report on the draft resolutions submitted to the meeting
  - 7.12 Document request form
  - 7.13 Form for voting by both mail or proxy
  - 7.14 Total number of voting rights existing and the number of shares comprising the capital on the publication date of the notice mentioned in article 225-73 of the French commercial Code, specifying, as applicable the number of shares and voting rights
  - 7.15 As applicable, the text and presentation of the reasons for the draft resolutions presented by shareholders
  - 7.16 As applicable, the list of items added to the agenda by the shareholders, accompanied by comments of the Board on these items.
  - 7.17 As applicable, the response of the Board to written questions submitted by the shareholders
  - 7.18 Meeting notice published in the BALO at D-15
  - 7.19 Video of the General Meeting
  - 7.20 Results of the votes
  - 7.21 Proceedings of the General Meeting
- PRESS RELEASES
- REGULATED INFORMATION
  - 9.1 Annual report
  - 9.2 Half year report
  - 9.3 Quaterly data
  - 9.4 Monthly Information on the total number of voting rights and the number of shares
  - 9.5 Description of the share buyback programs
  - 9.6 Permanent information
  - 9.10 Information on shareholding threshold
- CONTACTS
  - 10.1 Account Manager intermediary contact
  - 10.2 Press and Communications agency contact
- LEGAL NOTICE
2025 Key figures

€526 million
2,486 people
Essential products: €334m

VETOQUINOL LIVE SHARE PRICE

2025 results: 526 M€

Lastest press releases

05 Feb. 2026

Buyback programs -January 2026

05 Feb. 2026

Monthly information regarding the total number of voting rights – January 2026

29 Jan. 2026

Annual sales 2025: €526 million

en
fr

Select country

Europe

Austria

Belgium

Czech Republic

France

Germany

Ireland

Italy

Netherlands

Poland

Portugal

Slovakia

Spain

Sweden

Switzerland

United Kingdom

America

Brazil

Canada

Mexico

USA

Asia

China

India

Japan

South Korea

Oceania

Australia

New Zealand

Canada (Princeville)

Subtitle

Vetoquinol N.-A. Inc.

Breadcrumb

Home
Canada (Princeville)

World region

Americas

Phone number

(819) 364-3073

Fax number

(819) 364-7895

Address

700 Saint-Henri Street
G6L4X1 QC
Canada

Website URL

Website

Affiliate contacts

Johnny Lorenzo

Pharmacovigilance

You can contact us via our personalized form

Join Vetoquinol

Discover our job offers, internships and placements all around the world

Contact us

You can contact us by filling in our form

Vetoquinol Group

Vetoquinol is first and foremost an independent, family-owned business. Deeply committed to its values, it has always enjoyed a close relationship with its vet clients.

Lure Cedex
70204
FRANCE

Who are we ?
Our Products
Careers
Responsability
News

Press
Job offers
Investors

Footer bottom

General Terms of Use
Privacy and Cookies Policy
Legal Notice
Linkedin

© 2026 Vetoquinol